| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.088 | 0.02 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.086 | 0.03 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.03 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.03 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.092 | 0.03 |